-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $28

Benzinga·05/07/2026 16:30:44
Listen to the news
Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the price target from $25 to $28.